Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals. ... The latter will pay $325m upfront to acquire the global rights to Myalept, subject to an existing distributor

First FDA-backed treatment for rare disease lipodystrophy. AstraZeneca's Myalept has become the first approved treatment for the rare disease lipodystrophy after getting a green light from the FDA. ... Myalept will be "a much-needed treatment option for